Botfet / Company detail

SRPT

rejected

Sarepta Therapeutics, Inc.

biotech

Moat scoreNot available: not scored quality failout of 100

Rejectionquality_fail

The numbers

Financial metrics

Quality gate and thesis context

Roic-29.0%

Gross Margin59.9%

Revenue Cagr33.0%

Fcf Conversion43.1%

Fcf Yield-16.3%

Interest Coverage-66.6x

Market Cap B$1.9B

PeNot available: not applicable loss making

Quality PassFail

Founder LedNo

Thesis AlignedYes

Moat QuantNot available: not scored quality fail

Why it may endure

Quant: · Curator:

Market Share StabilityNot available: not scored quality fail

Network EffectsNot available: not scored quality fail

Pricing PowerNot available: not scored quality fail

Regulatory MoatNot available: not scored quality fail

Switching CostsNot available: not scored quality fail

ConvictionNot available: not scored quality fail

LeadershipNot available: not scored quality fail

VisionNot available: not scored quality fail